Transient Endothelial Damage Following FS-LASIK Combined With Corneal Cross-Linking Surgery: Case Report.

Am J Case RepSep 17, 2026 (epub)
Case ReportOphthalmology

Li Wang, Yun Wang, Xiaofeng Zhang

✦ AI-curated · Sources linked

Case in brief

An 18-year-old male with high myopia underwent FS-LASIK combined with corneal cross-linking. Postoperatively, he exhibited corneal edema and endothelial changes in both eyes by day 3. Endothelial microscopy revealed decreased cell density and hexagonal cell percentage. By one week, symptoms resolved, and by two months, visual acuity returned to 20/20 with endothelial metrics normalizing.

Diagnostic / clinical pearl

Clinicians should be aware of the potential for transient endothelial damage following FS-LASIK combined with corneal cross-linking, emphasizing the need for careful patient selection and preoperative counseling.

Source

PubMed · PMID 42752401

Published in Am J Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.